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Targeting MYC and HDAC8 with 
a Combination of siRNAs Inhibits 
Neuroblastoma Cells Proliferation 




HDAC8, c MYC and MYCN are involved in the tumorigenesis of neuroblastoma. 
A mouse Neuroblastoma (NB) tumor model was used to understand the role of 
miRNA, miR-665 in NB tumorigenesis and cellular differentiation. During cellular 
differentiation of NB cells there is an up regulated miRNA-665. We found that 
HDAC 8, c MYC and MYCN are the direct targets of mimic miR-665 which was 
validated by luciferase reporter plasmid with 3’ UTR and ELISA. Mimic miR-665 
inhibited cell proliferation, arrested cells in G1 stage and decreased S Phase in cell 
cycle. miR-665 increased the acetylation of histones and activated Caspase 3. This is 
the first report to recognize miRNA 665 as a suppressor miRNA of NB. The effects 
of miR-665 were confirmed with the transfection of siRNA for HDAC8 and siRNA 
for MYC. Individual siRNA- HDAC8 or siRNA-MYC inhibited 40–50% of cell 
proliferation in vitro, however, the treatment with the combination of both siRNA-
MYC + siRNA- HDAC8 inhibited 86% of cell proliferation. Indicating that both 
the targets c MYC and HDAC 8 should be reduced to obtain a significant inhibition 
of cell proliferation. Intratumoral treatment of xenograft tumors in mice with the 
combination of siRNA-MYC + siRNA- HDAC8 reduced the levels of target c-MYC 
protein by 64% and target HDAC 8 protein by 85% and the average tumor growth 
reduced by 80% compared to control tumors treated with NC-siRNA. Our results 
suggest the potential therapeutic effect of suppressor miR-665 and the combination 
of siRNA-MYC + siRNA-HDAC8 for neuroblastoma treatment.
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1. Introduction
Neuroblastoma is the most frequently diagnosed extracranial solid tumor in 
children. About 90% of cases occur in children less than 5 years old and it is rare 
in adults. Of cancer deaths in children, about 15% are due to neuroblastoma [1]. 
Chances of long-term survival, however, are less than 40% despite aggressive 
treatment [2].
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MYC is an oncogenic transcription factor that is overexpressed in many types 
of cancer. MYC has been shown to directly upregulate a protumorigenic group of 
miRNAs and represses several suppressor miRNAs, thus contributing to tumorigen-
esis [3]. For example, MYC overexpression can upregulate the oncogenic miR-17-92 
cluster, that are directly activated in lymphoma [4], and can also repress several 
suppressor miRNAs [3]. The MYC gene is amplified in various human cancers, 
including in lung carcinoma, breast carcinoma, and colon carcinoma [5].
Histone deacetylases affect gene expression by altering the histone acetyla-
tion status, and that as a consequence, HDAC overexpression contribute to 
tumorigenesis by affecting the expression of key mRNAs and miRNAs. HDACs 
are overexpressed in most cancers, leading to histone deacetylation, inhibition of 
growth- suppressive genes, and increased cell proliferation [6]. HDAC8 overexpres-
sion correlates with advanced neuroblastoma in patient tumor samples, and HDAC8 
inhibition reduced cell proliferation and induced neuroblastoma cell differentia-
tion [7]. HDAC inhibitors reduced the proliferation and induced the apoptosis of 
neuroblastoma cells in vitro and in vivo in mice [8, 9].
Given that both MYC and HDACs play an important role in the maintenance of 
the normal cellular physiological functions and that their overexpression is linked 
to neuroblastoma tumorigenesis, we asked whether the levels of both MYC and 
HDAC8 should be reduced to obtain significant inhibition of cell proliferation.
Our results demonstrate that miR-665 targets c-MYC and HDAC8 m RNA, 
miR-665 treatment also increased the percentage of cells in G1 phase and reduced 
the percentage of cells in S phase of the cell cycle. This is the first report to show 
that miR-665 is a suppressor miRNA directly targeting the 3’-UTR of c-MYC and 
HDAC8 in neuroblastoma [10].
We investigated the effects of small interfering RNAs (siRNAs) targeting 
HDAC8 and MYC in murine neuroblastoma cells. RNA interference is a process of 
posttranscriptional gene silencing in which a double stranded RNA inhibits gene 
expression in a sequence-dependent manner via degradation of the corresponding 
mRNA. siRNAs can be used as potent and specific tools for gene knockdown. Several 
laboratories have reported siRNA targeting of gene expression in cancer cells and the 
inhibition of cell proliferation in vitro and tumor growth in vivo [11–14].
We reported that in vitro, single-agent siRNA HDAC8 or siRNA-MYC inhibited 
cell proliferation by 40–50%; however, treatment with the combination of siRNA 
MYC + siRNA-HDAC8 inhibited cell proliferation by 86% [10]. To further confirm 
these findings in an animal model, we set out to verify if tumor growth can be 
inhibited in a neuroblastoma xenograft mouse model when tumors are treated with 
a combination of siRNA-MYC and siRNA HDAC8. Our findings from this study 
show that the tumor growth was reduced by 80% following intratumoral delivery 
of a combination of siRNAs targeting both MYC and HDAC8 simultaneously [15].
2. Materials and methods
2.1 Reagents
Cell culture media, DMEM with high glucose (D6429), essential and non-
essential amino acids (M5550, m7145), Bt2c AMP (D0627), the colorimetric 
Caspase 3 kit (Code CASP-3-C), and propidium iodide (P4170) were purchased 
from Sigma Aldrich, St. Louis. Fetal bovine serum (FBS) was purchased from 
Phenix Research Products, Candler, NC, USA. BD-Falcon tissue culture 96-well 
plates (353072) were purchased from BD Biosciences. The RNA extraction miR-
Neasy kit (Cat No. 217084) was purchased from Qiagen, Germantown, MD, USA. 
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The MTS Cell. Titer 96 Aqueous One Solution (Cat # G3580) cell proliferation assay 
was purchased from Promega Biotechnology, Madison,WI, USA. The HDAC Kit 
(#K331–100) was purchased from BioVision, Inc. Co rning. 96-well EIA/RIA plates 
(CLS3369) were used for ELISA. Antibodies for HDAC 8, H-145 (sc11405), C MYC, 
C-19 (SC-786), acetylated Histones, Ac- H2B, Lys 5/12/15/20 (SC-8652), Ac-H3, 
lys9 (sc-8655), Ac-H4, lys16 (sc-8662), and siRNA for c-MYC (pool of 4 different 
siRNA duplexes, sc-29227) were purchased from Santa Cruz Biotechnology, Dallas, 
TX, USA. Negative control #2 siRNA (#4390846), siRNA-HDAC 8 (S88696) and 
Lipofectamine RNAi Max (#13778075) were purchased from Life Technologies/
Ambion/ Invitrogen. Negative control miRNA Cel-miR-67 (#CN-001000) 
sequences based on C. elegans miRNA, mimic hsa-miR-665 (#C 301246–01), 
and transfection reagent Dharmafect Duo (#T2010–01) were purchased from 
Dharmacon. Luciferase expression plasmids with the 3’-UTR for HDAC8 
(#S804229), C-MYC (#S804638), MYCN (Product No S807230), or empty vector 
without 3’-UTR (#S890005), and the LightSwitch luciferase assay kit (#32031, 
LS010) were purchased from Active Motif, CA, USA.
2.2 Cells and cell culture
Mouse neuroblastoma cholinergic clonal cells (S20) were obtained from Dr. 
Marshall Nirenberg of The US National Institutes of Health (NIH). Cells were grown 
in monolayers in DMEM supplemented with essential and nonessential amino acids, 
penicillin/streptomycin, and 10% FBS at 37°C with 5% CO2 and humidity.
Neuroblastoma cells were plated in 96-well plates at 12x103 cells per well and 
After 48–72 h, cell viability was measured colorimetrically using the MTS Cell Titer 
96 Aqueous One Solution. Samples were incubated at 37°C for 3–4 h and samples 
were read at 490 nm in a plate reader according to the manufacturer’s instructions.
For cell cycle analysis, 1x106 cells were plated in T25 flasks. After 48 h, cells were 
trypsinized, treated with 75% ethanol and 100ug/ml RNAse A, and then stained 
with propodium iodide (PI). Untreated and (20,000 cells/ sample) were analyzed 
for cell cycle distribution via flow cytometry at the Core lab of Children’s Cancer 
Center Hospital, Houston, TX, USA.
2.3 Transfections
The effects of miR-665 or siRNA on cell proliferation were determined using 
reverse transfection. First, 100 nM negative control miRNA, miR-665, negative 
control siRNA, C-MYC siRNA, or HDAC8 siRNA was mixed with Lipofectamine 
RNAimax. This mixture was added to 12x103 cells, which were then plated in 
96-well plates. After 48–72 h, cell viability was measured using MTS Cell Titer 
96 Aqueous One Solution and incubated at 37°C for 3–4 h. Samples were read at 
490 nm according to manufacturer’s instructions.
miRNA effects on the cell cycle were assessed using reverse transfection of cells with 
100 nM negative control miRNA or miR-665 mimic plus Lipofectamine RNAimax. The 
transfection mixture was added to 1x106 cells, which were then plated in a T25 flask. 
After 48 h, cells were trypsinized, treated with 75% ethanol and 100ug/ml RNAse A, 
and then stained with PI. For cell cycle analysis, 20,000 cells/sample were analyzed via 
flow cytometry in the Core lab of Children’s Cancer Center Hospital, Houston, TX.
2.4 Whole cell extracts
Cell extracts were prepared from untreated,, and miRNA transfected cells 
for target assays. miRNA-transfected cells were reverse transfected with 100 nM 
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negative control miRNA, miR-665, negative control siRNA, c-MYC siRNA, or 
HDAC8 siRNA plus Lipofectamine RNAimax. Transfected cells were plated in T25 
flasks. After 48–72 h, cell extracts were prepared in assay buffer as described by 
Khandelia, et al. [16]. Assay buffer consisted of 20 mM Tris–HCL pH 7.5, 150 mM 
NaCl, 5 mM EDTA, 10% glycerol, 1% Nonidet P40, and protease inhibitor cocktail 
from Sigma (P8340). Protein concentrations were determined using Pierce’s BCA 
Assay as per the manufacturer’s instructions.
miR-665 inhibit cell growth compared to untreated cells and cells treated with 
negative control miRNA. Assays were normalized using equal concentrations of 
protein (50–100 ug) from untreated, negative control miRNA-, and miR-665- 
treated cells in assessing total HDAC and Caspase 3 activity, and HDAC8 and 
c-MYC levels via ELISA.
2.5 Quantitation of miR-665 in transfected cells
Mouse neuroblastoma cells were transfected with 100 nM miR-665 mimic 
and negative control cel-miR-67. 48 h post-transfection, total RNA was extracted 
from three biological replicates per treatment using the Qiagen RNEasy mini 
kit. miR-665 was quantitated via realtime qPCR by Arraystar, Inc. (Rockville, 
MD, USA).
Real-time PCR was performed for each RNA sample to quantify miR-665 and 
the housekeeping gene, U6. According to the standard curve, mRNA concentra-
tions in each sample are determined directly using Rotor-Gene Real-Time Analysis 
software v.6.0 and the 2∆∆Ct method.
2.6 Total HDAC activity
Total HDAC activity was measured in 50–75ug of protein from cell extracts 
prepared from untreated, or negative control miRNA- or miR 665-transfected cells 
using the Biovision kit (#K331–100). Acetylated HDAC substrate and other reagents 
were added according to the manufacturer’s instructions and the final deacetylated 
product was read at 405 nm in a plate reader.
2.7 HDAC8 and c-MYC protein quantitaion via ELISA
HDAC8 and c-MYC proteins were quantitated using cell extracts prepared 
from untreated or 1 mM Bt2cAMP treated cells, or negative control miRNA- or 
miR-665- transfected cells via ELISA. 100ug protein per sample was mixed 
with 0.02 M carbonate coating buffer (pH 9.5) and added to 96-well BD-Falcon 
ELISA plates.
Samples were incubated at 4°C for 15 h. Wells were blocked with 10% FBS in 
PBS, treated with antibodies (diluted 1:30) specific for HDAC8 (SC11405) or c-MYC 
(SC-798), and incubated at 37°C for 2 h. Samples were washed with PBS + 0.05% 
Tween, treated with goat anti-rabbit IgG.
HRP secondary antibody (diluted 1:500), and incubated at 37°C for 1 h. Wells 
were washed and treated with substrate TMB and incubated at room temperature 
for 30 min, and then the reaction was stopped with 2 N H2SO4. Samples were read at 
450 nm in a plate reader.
2.8 Caspase 3 activity
Caspase 3 activity was measured in 50ug protein from untreated, Bt2cAMP-
treated, or miR-665-transfected cells using Sigma Aldrich’s colorimeter kit (Code 
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CASP3-C). 50ug protein was mixed with the peptide substrate, Ac-DEVD-pNA 
(p-nitroanilide), in the presence of 10 mM DTT. Caspase 3 hydrolyzes the sub-
strate, releasing p-nitroaniline, which is read at 405 nm. The specificity of caspase 3 
activity was determined in the presence of the inhibitor, Ac-DEVD- CHO.
2.9 Target validation using luciferase expression plasmids
HepG2 cells were used for miR-665 target validation, because miR-665 does not 
inhibit the growth of these cells. When mouse neuroblastoma cells were used for 
target validation, the negative control luciferase vector plasmid without any target 
3’-UTR showed a 50% decrease in luciferase activity when co-transfected with miR-
665 compared to negative control miRNA. This decrease in luciferase activity was 
non-specific and was caused by cell growth inhibition due to miR-665 transfection.
To validate miR-665 targets, HepG2 cells were grown for 24 h in a 96-well plate. 
Cells were then co transfected with 100 ng luciferase expression plasmids contain-
ing the 3’-UTR for HDAC8, c-MYC, or MYCN, or the empty vector without any 
target 3’UTR, plus 100 nM negative control miRNA or miR-665 with Dharmafect 
Duo transfection agent. After 48 h of cotransfection, luciferase activity was mea-
sured using the Active Motifs LightSwitch luciferase assay kit. Luminescence was 
read on a Molecular Devices Soft Max Pro5 luminometer.
2.10 Histone acetylation
Histone acetylation was quantified via ELISA in cell extracts prepared from 
cells transfected with negative control miRNA, miR-665, negative control siRNA, 
or HDAC8 siRNA. 100ug protein was mixed with 0.02 M carbonate coating buf-
fer (pH 9.5), added to 96-well BD Falcon ELISA plates, and incubated at 4°C for 
15 h. Wells were blocked with 10% FBS in PBS, treated with acetylated antibodies 
(diluted 1:30) for Ac H2B (Lys 5/12/15/20), Ac-H3 (lys9), or Ac-H4 (lys16), and 
incubated at 37°C for 2 h. Samples were washed with PBS + 0.05% Tween, treated 
with an appropriate HRP-conjugated secondary antibody (diluted 1:500), and 
incubated at 37°C for 1 h. Wells were washed and treated with substrate TMB and 
incubated at room temperature for 30 min, and then the reaction was stopped using 
2 N H2SO4. Samples were read at 450 nm in a plate reader.
2.11 Neuroblastoma tumor model
Mice experiments were performed with the approval of the institutional Animal 
Care and Use Committee, IACUC at Nanospectra Biosciences Inc. Houston, Texas.
A/J female mice six weeks old were purchased from Jackson Laboratory, Bar 
Harbor, Maine, USA. Murine neuroblastoma cells, 1x106 cells in DMEM media with 
50% matrigel in 100 ul without fetal bovine serum and without antibiotics were 
subcutaneously injected on the right flanks. After 12 days, tumor growth can be 
seen and tumors were measured with a caliper.
When tumors reached 100 mm3 in size, mice were divided into two groups with 
8–10 mice in each group.
Intratumoral delivery of siRNA.




siRNA-MYC (S70224), Sense Sequence: (5′------3′).
AGGUAGUGAUCCUCAAAAAtt.
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Antisense Sequence: UUUUUGAGGAUCACUACCUtg.
Negative control #2 siRNA (#4390846), and Lipofectamine RNAi Max 
(#13778075) were purchased from Life Technologies/Ambion.
A total of 3 nmol Negative control siRNA or 3 nmol combinations of siRNA-
MYC + siRNA-HDAC8 were mixed with Lipofectamine RNAi max (Liposome) 
in DMEM media without fetal bovine serum and without antibiotic. siRNA 
complexed with Lipofectamine in a volume of 30 ul was delivered into tumors 
by intratumoral injection every third day. Tumors were measured every second 
day with a caliper and mice were weighed every third day. Tumor volume was 
calculator with a formula, V = Length X width2/2. Experiment was stopped when 
the control tumors treated with negative control siRNA reached a tumor burden 
volume of 1200 mm3. Mice were euthanized by CO2 inhalation 2 days after last 
treatment with siRNA. Tumors were removed and weighed. Tumors were frozen 
in liquid nitrogen and stored at -80o C freezers until used for preparation of tumor 
extracts for ELISA.
2.12 Tumor extract preparation
Tumors treated with NC-siRNA or with combined siRNA-HDAC8 + siRNA-MYC 
were cut into small pieces and homogenized in assay buffer in a glass homogenizer. 
Assay buffer as described by Khandelia et al. [16], consisted of 20 mM Tris–HCL 
pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Nonidet P40, and protease 
inhibitor cocktail from Sigma (P8340). Protein concentrations were determined 
using Pierce’s BCA Assay as per the manufacturer’s instructions.
2.13 Statistical analysis
Error bars represent standard error of the mean (SEM) from 2 to 3 biologi-
cal replicates from 3 to 5 independent experiments. P-values were calculated 
using T.Test (2 tailed, 3 samples, unequal variance) and p < 0.05 was considered 
 statistically significant.
3. Results
3.1 miR-665 inhibits cell proliferation
NB cells transfected with miR-665 show changes in cell morphology, lost the 
normal spindle shape and cells grew in clumps without processes compared to cells 
transfected with negative control miRNA (Figure 1A and B). Cell cycle analysis 
results show that miR-665 treated cells show an increase of 16% of cells in G1 phase 
of cell cycle and the cell number decreased by 18% in S phase compared to nega-
tive control miRNA transfected cells. miR-665 treatment did not affect the cells in 
G2 phase (Figure 1C). Cell viability decreased proportionally with the increasing 
concentration of miR-665, represented by black bars (Figure 1D).
3.2 miR-665 targets HDAC 8, c MYC and MYCN
Computational algorithm prediction site TargetScan and miRanda (microRNA.
org) predicts mRNA targets for Mirna. miranda predicted hsa-miR-665 targets 3’ 
UTR of HDAC 8 and the sequence alignment is presented in Figure 2A. miranda, 
also predicts that hsa-miR-665 targets MYCN 3’ UTR and the sequence alignment is 
presented in Figure 2B.
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MYC is overexpressed in 30% of all human cancers and frequently predicts for 
a poor clinical outcome, and deregulated expression of MYC is a hallmark feature 
of cancer [3] miRanda and Targetscan did not include 3’ UTR of C MYC as miR-
665 target. Therefore, Complimentary sequences between miR-665 and 3’ UTR of 
C MYC were compared at online pairwise sequence alignment site www.ebi.ac.uk. 
Results show two complementary binding sites for miR-665 in the 3’ UTR of c 
MYC (Figure 2C).
First we measured total HDAC activity in the cell extracts prepared from nega-
tive control miRNA and miR-665 transfected cells in the presence of acetylated 
HDAC substrate Ac-Lys (Ac)-p NA and deacetylated end product was measured 
colorimetrically. HDAC 8 and c MYC proteins were measured with antibody in 
ELISA. The results show that total Pan HDAC activity was decreased by 40%, and 
HDAC 8 and c MYC proteins were decreased by 40% in miR-665 transfected cells 
compared to negative control miRNA treated cells (Figure 3A–C).
Next, we tested whether HDAC 8, c MYC and MYCN genes are the direct target 
of miR-665. In these experiments HepG2 cells were used because miR-665 does 
not affect the growth of these cells (our unpublished results). Luciferase reporter 
Figure 1. 
miR-665 effects on cell proliferation (A) cells treated with 100 nM negative control miRNA and miR-665 (B) for 
72 hr. were prepared for cell cycle distribution analysis. Propidium iodide stained cells were analyzed by FLOW 
cytometry (C) Several concentration of miR-665 effect on cell viability (D) STDEV was used for +/− standard 
error bar; data is from 2 independent experiments with 3 biological replicates for each experiment was used. 
(figures were printed from published article in “Oncotarget”, N.Prashad Vol 9, 33186–33201, 2018).
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plasmids with 3’ UTR were cotransfected with negative control miRNA and miR-
665 in HepG2 cells and after 48 hr. luciferase activity were measured in cell extracts. 
Results show a 40% decrease in luciferase activity of HDAC 8 3’ UTR, a 51% 
decrease in luciferase activity of c MYC 3’ UTR and a 50% decrease in luciferase 
activity of MYCN 3’UTR from the cells co transfected with miR-665 compared to 
the co transfection with negative control miRNA (Figure 2D). These results vali-
date that m RNAs of HDAC 8, c MYC and MYCN are the direct targets of suppressor 
miR-665.
Figure 2. 
Predicted binding sites for miR-665 in targets HDAC 8, c MYC and MYCN 3’ UTR. Computational prediction 
site miRanda (microRNA.org) predicted hsa-miR-665 targets 3’ UTR of HDAC 8 and the sequence alignment 
is presented in (A). miranda, also predicts that hsa-miR-665 targets MYCN 3’ UTR and the sequence 
alignment is presented in (B). miranda and Targetscan did not include 3’ UTR of C MYC as miR-665 target. 
Therefore, complimentary sequences between miR-665 and 3’ UTR of C MYC were compared at online 
pairwise sequence alignment site www.ebi.ac.uk. Sequence alignment is presented in (C). (D) miR-665 targets 
were validated by co transfection of 100 ng luciferase expression plasmids with 3’-UTR and 100 nM negative 
control miRNA and miR-665 into HepG2 cells. Empty vector without 3’ UTR was used as a control. After 
48 hr., luciferase activity was measured and normalized luciferase activity is presented. Data is presented from 
2 independent experiments with 3 biological replicates were used. STDEV was used for +/− standard error bar. 
(figures were printed from published article in “Oncotarget”, N.Prashad Vol 9, 33186–33201, 2018).
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3.3 MiR-665 induced activation of caspase 3
HDAC inhibitors induce the caspase 3-dependent apoptosis [8] Suppressor 
miR-34a increased the activation of caspase 3 and caused caspase dependent 
apoptosis in neuroblastoma cells [17, 18]. Caspase 3 is a critical part of apoptosis, 
and is required for the DNA fragmentation and for the typical morphological 
changes of cells undergoing apoptosis. We investigated the effect of miR-665 on 
the activation of caspase 3 and activity was measured by the hydrolysis of the 
peptide substrate attached to p-nitroanilid. Caspase 3 activity was measured in 
cell extracts prepared from cells transfected with negative control miRNA and 
miR-665. Results show that caspase 3 activity was increased by 2.5-fold in miR-665 
transfected cells compared to negative control miRNA (Figure 3D). Specificity of 
the caspase 3 was determined by the addition of caspase 3 inhibitor TSA before the 
addition of substrate in the assay. The results show that inhibitor binds to caspase 
3 and inhibited 90% of miR-665 activated caspase 3 activity (Figure 3D). These 
Figure 3. 
miR-665 effect on target HDAC 8, c MYC and MYCN cell extracts from100nM negative control miRNA and 
miR-665 transfected cells were used for the quantitation of; (A) total HDAC activity, (B) HDAC8 protein 
by ELISA, (C) c MYC protein by ELISA and (D) caspase 3 activity and specificity of caspase 3 enzyme 
activity was determined in the presence of inhibitor. Data is presented from 2 independent experiments with 
3 biological replicates were used. STDEV was used for +/− standard error bar. (figures were printed from 
published article in “Oncotarget”, N.Prashad Vol 9, 33186–33201, 2018).
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results show that mimic miR-665 activated caspase 3 in neuroblastoma cells, sug-
gesting that miR-665 can inhibit cell growth and reduced viable cells by caspase 3 
dependent apoptosis.
3.4 miR-665 levels following transfection
miR-665 levles were quantitated in neuroblastoma cells transfected with nega-
tive control miRNA and miR 665 using real time qPCR. Mouse neuroblastoma 
cells have very low levels of endogenous miR-665 (Figure 4A); however, miR-665 
expression increased 848-fold in cells transfected with mimic miR-665 compared to 
cells transfected with the negative control miRNA, cel miR-67 (Figure 4A and B). 
miRNA levels reportedly increased by over 1000-fold in cells transfected with miR 
200a [19]. Our results strongly indicate that miR-665 upregulation decreased MYC 
and HDAC8 expression, thus inhibiting proliferation and inducing apoptosis in 
mouse neuroblastoma cells.
Figure 4. 
Quantitation of miR-665 in transfected cells. miR-665 was quantitated via real-time qPCR normalized to the 
U6 gene from three biological replicates 48 h after transfection with negative control miRNA (cel-miR-67) or 
miR-665. From left, lane 1 and 14 (M), show DNA molecular weight ladder (A) lanes 2–7 (NC-1–NC3 and 
665–1–665-3) show the U6 gene. Lanes 8–10 (NC-1–NC3) show miR-665 levels from cells transfected with 
negative control miRNA. Lanes 11–13 (665–1–665-3) show miR-665 levels from cells transfected with miR-665. 
The miR-665 fold increase in miR-665-transfected cells was quantitated using the 2-ΔΔCt method (B) miR665 
levels are shown in cells transfected with negative control miRNA (black bar) and in miR-665-transfected cells 
(white). Error bars were calculated from the standard deviation from three biological replicates. *P < 0.54x10–6. 
(figures were printed from published article in “Oncotarget”, N.Prashad Vol 9, 33186–33201, 2018).
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3.5 siRNA effect on mouse neuroblastoma cells
miRNA targets hundreds of m RNAs and suppresses their expression, however, 
siRNA targets a specific m RNA. In these experiments, siRNA for HDAC 8 (siRNA-
HDAC 8) and siRNA for MYC (siRNA-c MYC) were used to substantiate the effects 
of miR-665 on neuroblastoma cells.
3.6 SiRNA effect on cell proliferation
NB cells were transfected with negative control siRNA, siRNA-HDAC 8, 
siRNA-c MYC and the combination of siRNA-HDAC 8 + siRNA-c MYC. After 
48 hr. of growth, cell viability was determined with CellTiter assay (Promega). 
SiRNA-HDAC8 inhibited 42% and siRNA-c MYC inhibited 55% of cell prolifera-
tion, however, the combination of both siRNAs inhibited 86% of the growth of 
the cells (Figure 5A). Therefore, the combination of siRNA-HDAC8 plus siRNA-c 
MYC was more targeted towards mRNA of HDAC8 and c MYC and caused more 
effective apoptosis and loss of cells. These results show that HDAC 8 and MYC 
are critical targets and inhibition of both targets is required for the inhibition of 
neuroblastoma.
3.7 SiRNA effect on HDAC 8 and C MYC
HDAC 8 and c MYC proteins were quantitated by antibody in ELISA in cell 
extracts prepared from the cells transfected with negative control siRNA and 
siRNA-HDAC 8. The results show that siRNA-HDAC 8 transfection inhibited 
40% of HDAC 8 proteins (Figure 5B) as well as inhibited 35% of MYC protein. 
Inhibition of MYC may be indirect effect of HDAC 8 inhibition. HDAC8 inhibition 
increases acetylation of histones and alters gene expression, thus decreasing MYC 
expression. Therefore, miR-665 represses the expression of c MYC both at the 
transcription and at the post transcription levels. siRNA-HDAC 8 and siRNA-c MYC 
substantiated the effects of miR-665 on neuroblastoma cells.
3.8 siRNA activates caspase 3
Caspase 3 activity was measured in the cell extracts prepared from cells 
transfected with negative control siRNA, siRNA-HDAC8 and siRNA-c MYC. The 
results show that siRNA-HADC8 increased the activity of caspase 3 by 1.8-fold and 
siRNA –c MYC increased the activity of caspase 3 by 2.5-fold compared to negative 
control siRNA (Figure 5C). Therefore, the results of siRNA effects substantiate the 
effects of miR-665 on the activation of caspase 3.
3.9 Effect of miR-665 and siRNAs on histone acetylation
Our results show that miR-665 and siRNA-HADC8, decreased total HDAC 
activity and decrease HDAC 8 protein, therefore, we measured the acetylation of 
histones in the cell extracts and the results were compared among all treatments. 
MiR-665 transfected cells show increases in the acetylation of histones Ac-H2B 
by 25%, Ac-H3 by 40% and Ac-H4 by 50% compared to negative control miRNA 
transfected cells (Figure 6A). miR-665 acetylates predominantly H3 and H4 
histones.
Likewise, Si RNA-HDAC8 treated cells also show increases in the acetylation of 
histones Ac-H2B by 38%, acetylation of Ac-H3 by 58% and show higher acetyla-
tion of Ac-H4 by 2-fold (200%) compared to negative control siRNA treated cells 
Pheochromocytoma, Paraganglioma and Neuroblastoma
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(Figure 6B). siRNA-HDAC8 acetylated predominately AC-H4 and correlate with 
the results of miR-665.
3.10 miR-665 targets c-MYC and HDAC8
Taken together, our results indicate that miR-665 targets c-MYC and HDAC8, 
decreasing their expression, increasing histone acetylation, and modulating 
expression of cell proliferation related genes. We propose a model (Figure 7) 
Figure 5. 
siRNA effects on neuroblastoma cells.siRNA specific for HDAC8 (siRNA-HDAC8) or c-MYC (siRNA-c-MYC, 
a mixture of 4 siRNAs) were used to confirm the effects of miR665 in neuroblastoma cells. (A) siRNA effect 
on cell proliferation. Neuroblastoma cells were transfected with 50 nM siRNA-HDAC8, 100 nM siRNA-c-
MYC, or both siRNAs together. Cell viability was measured via MTS assay. SEM bars represent the standard 
deviation from two independent experiments with three biological replicates each. *P < 0.005, **P < 0.001, 
***P = 6.8x10–5. (B) Cell extracts from negative control siRNA- or siRNA-HDAC8-treated cells were used 
to quantify HDAC8 levels via ELISA. HDAC8 was down regulated in HDAC8-siRNA-transfected cells 
*P < 0.04. (C) Caspase 3 activity was quantified in cell extracts via Casp-3 kit. Caspase 3 activity increased 
in siRNA-HDAC8- and siRNA-c-MYC-transfected cells. SEM bars represent the standard deviation from two 
independent experiments with two biological replicates each. *P < 0.01, **P < 0.004. (figures were printed 
from published article in “Oncotarget”, N.Prashad Vol 9, 33186–33201, 2018).
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illustrating suppressor miR-665 involvement in the inhibition of neuroblastoma 
cell proliferation [10].
3.11  Effects of combination of siRNA-HDAC 8 ± siRNA-MYC on neuroblastoma 
cells in vitro
When cells were treated with the combination of siRNA HDAC 8 + siRNA-MYC, 
cell proliferation was inhibited by 86% [10]. Therefore, HDAC 8 and MYC are criti-
cal targets and effective blockade of both targets is required to ensure a maximum 
inhibition of neuroblastoma cell proliferation.
On the basis of these results, we hypothesized that neuroblastoma tumor 
xenograft growth in mice can be inhibited when treated with the combination of 
siRNA-MYC + siRNA- HDAC8.
Figure 6. 
Histone acetylation. Cell extracts from negative control miRNA-, miR-665-, negative control siRNA-, or 
siRNA-HDAC8 treated cells were used to quantitate histone acetylation via ELISA. Data represent standard 
deviations from two independent experiments. Negative control miRNA (white) and miR-665 transfection 
increased histone acetylation (black) (A) *P < 0.01, **P < 0.01, ***P < 0.04. Negative control siRNA (white) 
and siRNA-HDAC8 increased histone acetylation (black) (B) *P < 0.008, **P < 0.04, ***P < 0.001.
Figure 7. 
Proposed model illustrating how suppressor miR-665 targets c-MYC and HDAC8 to inhibit neuroblastoma cell 
proliferation and maintain cellular homeostasis. (figures were printed from published article in “Oncotarget”, 
N.Prashad Vol 9, 33186–33201, 2018).
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Figure 8. 
(A) Effect of combination of siRNA on the growth of neuroblastoma tumor. Murine neuroblastoma cells, 1 × 106 
cells in DMEM media with 50% matrigel in 100 ul were subcutaneously injected on the right flanks. After 
12 days, tumor growth can be seen and tumors were measured with a caliper. When tumors reached 100 mm3 
in size, mice were divided into two groups with 8 mice in each group. Negative control siRNA or combination 
of siRNA-MYC + siRNA-HDAC8 was mixed with Lipofectamine RNAi max (liposome) in DMEM media 
without fetal bovine serum and without antibiotic. siRNA complexed with Lipofectamine in a volume of 30 ul 
was delivered into tumors by intratumoral injection every third day. Tumors were measured every second day 
with a caliper and mice were weighed every third day. Tumor volume was calculator with a formula, V = length 
× width 2 /2. The numbers on X-axis show the number of siRNA treatments. Control tumor growth is shown by 
diamond (^) markers and the growth of tumors treated with siRNAs is shown by round (0) markers. SEM bars 
represent the standard deviation from 8 mice at each point P* < 0.031. (figure is printed from published article 
in “J. Cancer Biology and Therapeutics” N. Prashad V 6: 301–307 2020). (B) Mice with control and combination 
of siRNA treated tumors. Top row of mice with control tumors treated with NC siRNA and the bottom row of 
mice with tumors treated with the combination of siRNA-MYC + siRNA-HDAC. (C) Tumors from control and 
combination of siRNA treated mice. Top row representative control tumors treated with NC-siRNA and the 
bottom row representative tumors treated with the combination of siRNA-MYC + siRNA-HDAC8. (figure is 
printed from published article in “J. Cancer biology and therapeutics” N. Prashad V 6: 301–307 2020).  
(D) Weights of control and combination of siRNA treated tumors. Average of 8 control tumors was 1 gram and 
average of 8 tumors treated with combination of siRNA MYC + siRNA-HDAC8 was 0.186 gram. SEM bars 
represent the standard deviation from 8 tumors P** < 0.004.
3.12  Neuroblastoma tumor treatment with the combination of  
siRNA-HDAC8 + siRNA-MYC
We explored the therapeutic effect of the combination of siRNA-
HDAC8 + siRNA-MYC treatment on neuroblastoma tumor xenograft in mice. A 
total of 1x106 mouse neuroblastoma cells in 50% Matrigel were inoculated sub-
cutaneously in 6 weeks old female A/J mice. Tumors were formed with an average 
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volume of 100 mm3, 12 days after cells were inoculated. A 3 nmol negative control 
siRNA (NC-siRNA) or a 3 nmol combination of siRNA-HDAC + siRNA-MYC 
complexed with Lipofectamine RNAi max (Invitrogen) were inoculated into 10 
tumors each by intratumoral injections every 3rd day. Tumor growth was measured 
every 2 days with a caliper and volume was calculated with the formula, length X 
width2/2. The growth of control tumors treated with NC-siRNA increased, how-
ever, the tumors treated with the combination of siRNA-HDAC8 + siRNA-MYC 
show inhibition of the growth of tumors (Figure 8A). The rates of tumor growth 
were significantly decreased when treated with combined siRNA-MYC + siRNA-
HDAC8 compared to tumors treated with control negative siRNA.
All mice experiments were performed under IACUC approved animal study 
protocol.
Experiment was stopped when the control tumors reached an average volume 
of over 1200 mm3, then mice were euthanized by CO2 and tumors were removed 
and weighed. Pictures of mice with tumors were taken before tumors were removed 
(Figure 8B) and pictures of tumors removed and weighed are shown in (Figure 8C). 
The average wet weight of 8 control tumors treated with NC-siRNA and tumors treated 
with combination of siRNA-HDAC + siRNA-MYC is presented in Figure 8D. The 
average weight of tumors treated with the combination of siRNA-HDAC8 + siRNA-
MYC was decreased by 5-fold [0.186 g] compared to average weight of control tumors 
[1 g] treated with NC-siRNA. Tumor xenograft experiment was repeated twice 
with 10 mice treated with NC-siRNA and 10 mice treated with a combination of 
siRNA-HDAC8 + siRNA-MYC.
3.13 The quantitation of targets HDAC 8 and MYC in tumors
Tumor targets HDAC 8 and MYC proteins were quantitated by ELISA in extracts 
prepared from tumors treated with negative control siRNA and combination of 
siRNA-HDAC 8 + siRNA-MYC treated tumors. The results indicate that targets 
HDAC 8 and MYC were decreased by 85% and 65% in tumors treated with the 
Figure 9. 
(A, B) Quantitation of Myc and Hdac8 proteins from control and combination of siRNA treated tumors. 
Tumor targets Hdac8 and Myc proteins were quantitated by ELISA in extracts prepared from 3 tumors treated 
with negative control siRNA and 3 tumors treated with the combination of siRNA-HDAC 8 + siRNA-MYC. 
Average targets Hdac8 (A) and Myc (B) proteins were decreased by 85% and 65% in tumors treated with 
the combination of siRNA-HDAC8 + siRNA-MYC compared to tumors treated with NC-siRNA. SEM bars 
represent the standard deviation from 3 tumors (P* < 0.030, P** < 0.01). (figures printed from the article 
published in “J Cancer Biol Therap,” N. Prashad 6(1): 301–307 (2020)).
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combination of siRNA-HDAC8 + siRNA-MYC compared to tumors treated with 
NC-siRNA (Figure 9A and B).
The results indicate that a decrease in the tumor targets HDAC 8 and MYC 
caused the inhibition of the growth of tumors.
4. Discussion
miRNAs are both oncogenic and tumor suppressors. In normal cells homeostasis 
is maintained by keeping equilibrium between oncogenic and suppressor miRNA. If 
this equilibrium is disrupted that can cause dysfunction with increases in oncogenic 
miRNA and decreases in suppressor miRNA. A decrease in a specific suppressor 
miRNA can cause overexpression of HDCAs, c MYC and MYCN which can alter 
gene expression and cause cancer. However, when suppressor miRNAs are added 
exogenously to these cells then these cells restore normal properties and show 
growth arrest and apoptosis Therefore, suppressor miRNAs seem to be critical in 
the maintenance of cellular homeostasis.
A decrease in suppressor miRNA can over express genes like c MYC, MYCN and 
HDACs and cause cancers. Over expression of c MYC and MYCN cause the down regu-
lation of suppressor miRNAs. HDACs indirectly effect gene expression by the deacety-
lation of histones, therefore, this process can also effect the expression of miRNA.
Transfection of miR-665 into murine NB cells caused growth inhibition, cell 
cycle arrest, decreased total HDAC activity, decreased HDAC8 and MYC protein 
expression, activated caspase 3 and increased the acetylation of histones. miR-
665 targets HDAC8, c MYC and MYCN oncogene and decreases their expres-
sion. These targets are validated by the co- transfection of luciferase reporter 
with target 3’ UTR and miRNA-665. Therefore, miRNA 665 directly targets 
HDAC 8, MYCN and c MYC in the inhibition of mouse neuroblastoma cells. 
This is the first report to show that miR-665 is a suppressor miRNA of mouse 
neuroblastoma.
In targeted therapy of cancer, critical genes and proteins involved in the tumori-
genesis are identified and therapeutic agents’ miRNA and siRNA are used to inhibit 
the expression of target genes to inhibit the growth of cells in vitro and in vivo. 
SiRNA-mediated gene knockdown is much more potent and specific with only one 
mRNA target, whereas miRNA has multiple mRNA targets. siRNA therapeutic 
approach was used in gene targeting overexpressed cancer proteins in inhibiting 
cancer cell growth in vitro and inhibited tumor growth in vivo in the following 
mouse models: breast cancer mouse model, Glioma cells tumor and colon cancer 
tumor. MYCN, c-MYC, and HDAC8 may each contribute to neuroblastoma tumori-
genesis. We reported that transfection of mimic suppressor miR-665 inhibited the 
expression of c-MYC and HDAC 8 and increased caspase 3 involved in apoptosis 
and inhibited the growth of neuroblastoma cells in vitro [10].
Our data also indicate that both c-MYC and HDAC 8 are critical targets and 
targeting these two targets with siRNA inhibited cell growth by 86% in vitro. The 
combination of siRNAs inhibited tumor growth in vivo by 80%, therefore, inhibit-
ing more than one target is critical for the successful treatment of tumors in vivo.
5. Conclusion
Neuroblastoma is the most frequently diagnosed extracranial solid tumor in 
children. These tumors account for 15% of childhood deaths from cancer. Survival 
in one- year-old children is <30% despite aggressive therapies.
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We used mouse neuroblastoma tumor model and identified MYC and HDAC8 
are the critical targets in neuroblastoma tumorigenesis. Treatment of the tumors in 
mice with the combination of siRNA-MYC + siRNA-HDAC8 inhibited both the tar-
gets MYC and HDAC8 simultaneously and inhibited the growth of tumor by 80%. 
Therefore, inhibiting more than one target is critical for the successful treatment of 
tumors in vivo.
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